Brown Advisory Inc. Has $69.27 Million Stock Holdings in Illumina, Inc. $ILMN

Brown Advisory Inc. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 75.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 725,987 shares of the life sciences company’s stock after selling 2,183,241 shares during the period. Brown Advisory Inc. owned 0.47% of Illumina worth $69,266,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ILMN. Parkside Financial Bank & Trust boosted its stake in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the last quarter. Rise Advisors LLC lifted its holdings in Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after buying an additional 224 shares during the period. Cullen Frost Bankers Inc. bought a new position in Illumina in the second quarter valued at approximately $41,000. NewSquare Capital LLC grew its holdings in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares during the period. Finally, Evelyn Partners Investment Management LLP raised its position in shares of Illumina by 4,927.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after acquiring an additional 542 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Up 0.7%

Shares of ILMN stock opened at $128.96 on Friday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average of $111.21 and a 200-day moving average of $100.80. The company has a market capitalization of $19.71 billion, a price-to-earnings ratio of 28.91, a P/E/G ratio of 2.29 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm’s revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Barclays raised their target price on Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a report on Friday, October 31st. JPMorgan Chase & Co. upped their price target on Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Canaccord Genuity Group lifted their price objective on shares of Illumina from $105.00 to $112.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. Finally, Daiwa Capital Markets downgraded shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $115.00.

Insider Buying and Selling at Illumina

In other news, Director Scott Gottlieb acquired 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the acquisition, the director owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.60% of the stock is owned by corporate insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.